vedolizumab

Type: Keyphrase
Name: vedolizumab
First reported Sep 18 2014 - Updated Sep 18 2014 - 1 reports

Opportunity for emerging agents in Crohn’s disease, report finds

New research from Decision Resources Group has found that only a small proportion of patients with Crohn's disease/ulcerative colitis (CD/UC) eligible for biologic therapy currently receive a biologic.Gastroenterologists surveyed by the group cite patients' ... [Published Pharma Letter - Sep 18 2014]
First reported Sep 03 2014 - Updated Sep 03 2014 - 1 reports

Consumer Reports shares best buy for treating Crohn's disease

There are a variety of options for treating Crohn's disease that can leave people diagnosed with the disease confused. Some medications are costly while others have side effects that are intolerable. When talking with your doctor how can you choose the ... [Published EMax Health - Sep 03 2014]
First reported Sep 02 2014 - Updated Sep 02 2014 - 1 reports

Sofosbuvir and vedolizumab knocked back

The Pharmaceutical Benefits Advisory Committee has rejected submissions for the PBS listing of sofosbuvir (Sovaldi) for hepatitis C and vedolizumab (Entyvio) for moderate to severe ulcerative colitis.Subsidising the direct-acting hep C antiviral would ... [Published Gastroenterology Update - Sep 02 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Takeda launches first gut-selective treatment for inflammatory bowel disease in the UK

The first gut-selective treatment for ulcerative colitis and Crohn’s disease is now available in the UK, following licensing by European regulators. Receiving its first launch, Entyvio (vedolizumab) is a new class of therapy, working selectively in the ... [Published Pharma Letter - Aug 28 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 2 reports

Drug hope for Crohn's patients: New treatment is first to work in the gut to target symptoms on the disease

A new drug could bring relief for the 250,000 Britons who have the serious bowel disorder Crohn’s disease.Vedolizumab is the first to work directly in the gut lining, targeting the inflammation that causes chronic symptoms such as diarrhoea, bleeding ... [Published NewsRT.co.uk - Aug 28 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 1 reports

Three UC drugs approved by FDA

As a disease with both chronic and acute manifestations, ulcerative colitis often requires a balancing act of maintenance and rescue therapies. While management of this condition is often a lifelong endeavor, severe, acute episodes also may occur, requiring ... [Published Orthopedics Today - Aug 25 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

Top medicine articles for July 2014

A collection of some interesting medical articles published recently: Migraines Linked to Increased Risk of 'Silent Strokes' http://buff.ly/1hTE5Ru Doctor’s Salaries Are Not the Big Cost - NYTimes http://buff.ly/QWe2lx  -- "There is a startling ... [Published Clinical Cases and Images: CasesBlog - Jul 23 2014]
First reported Jun 16 2014 - Updated Jun 16 2014 - 1 reports

ENTYVIO™ (vedolizumab) Now Available in the United States for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis and Crohn's Disease

DEERFIELD, Ill., and OSAKA, Japan, June 16, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced the United States (U.S.) commercial availability of ... [Published PR Newswire: General Business - Jun 16 2014]
First reported May 26 2014 - Updated May 28 2014 - 2 reports

Takeda Receives European Commission Marketing Authorisation for Entyvio(R) (vedolizumab) for the Treatment of Ulcerative Colitis and Crohn’s Disease

Zurich And Osaka, Japan (ots/PRNewswire) – Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission (EC) has granted Marketing Authorisation for Entyvio(R) ... [Published PRESSEMITTEILUNGEN - May 27 2014]
First reported May 23 2014 - Updated May 23 2014 - 1 reports

ENTYVIO (Vedolizumab) Injection, Powder, Lyophilized, For Solution [Takeda Pharmaceuticals America, Inc.]

First reported May 20 2014 - Updated May 21 2014 - 3 reports

Takeda's Entyvio gets FDA approval to treat ulcerative colitis, Crohn's disease

Japan-based Takeda Pharmaceutical Company (Takeda) and its wholly-owned subsidiary Takeda Pharmaceuticals USA have received approval from the US Food and Drug Administration (FDA) for a new biologic therapy, Entyvio (vedolizumab), to treat adults with ... [Published PBR - News - May 21 2014]
First reported May 20 2014 - Updated May 21 2014 - 2 reports

FDA Approves Takeda's Entyvio™ (vedolizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

DEERFIELD, Ill. and OSAKA, Japan, May 20, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States (U.S.) Food and Drug Administration ... [Published PR Newswire: Policy & Public Interest - May 20 2014]

Quotes

Dr Reske added: "By the end of 2017, biosimilars will account for at least one-quarter of the patient share currently captured by Remicade and Humira. The availability of biosimilars on formularies will depend on their price discount to the brand with savings of at least 20 percent likely needed to merit widespread formulary inclusion. At these discounts, MCOs will encourage use of the biosimilar before the brand through lower co-pays."
..." 25% of US adults consult online physician-rating sites - Doctors Check Online Ratings From Patients and Make Changes. Online ratings "can be pretty brutal. However, part of being a physician now is having to deal with these.” "When we decided to quit ignoring it and embraced it, it totally changed the game" - WSJ http://buff.ly/1mQ5XLC FDA Approves New Drug for Crohn Disease and UC: vedolizumab (Entyvio) , an injectable monoclonal antibody. Vedolizumab, an integrin receptor antagonist http://buff.ly/1lFuRtv Interferon-free regimen with 3 drugs effective in Hep C with Cirrhosis (ABT-450/r–Ombitasvir, Dasabuvir, Ribavirin) http://buff.ly/1o8pDMS -- Combination of nucleotide polymerase inhibitor sofosbuvir and antiviral ribavirin effective in HCV Genotypes 2 and 3 http://buff.ly/1o8pWr1 The relative risk reduction of 20% in breast-cancer mortality associated with mammography comes at a price. Abolish Mammography Screening Programs, says the SwissSwiss Medical Board. The report caused an uproar http://buff.ly/1o8qgGo In obese patients with uncontrolled DM2, intensive medical therapy plus bariatric surgery was better than drugs alone http://buff.ly/1o8qD3G First dialysis machine was made with aluminium from a bomber that was shot down and bits from an automobile engine http://buff.ly/1om861k At least 10% of adults and nearly all children who receive renal-replacement therapy have an inherited kidney disease http://buff.ly/1n8078E Kidney disease in farming communities worldwide remains a mystery : heavy metals and pesticides? indigenous herbs? OTC pain killers? chronic dehydration? http://buff.ly/1n80qjy Worldwide, chronic kidney disease affects 8—16% of population , number of deaths almost doubled in the past decade http://buff.ly/1n80MHa The articles were selected from Twitter and my RSS subscriptions. Please feel free to send suggestions for articles to clinicalcases AT gmail.com and you will receive acknowledgement in the next edition of this publication. "
"With the development of vedolizumab, Takeda is building upon this heritage and expanding into innovative therapies with a new biologic treatment" Smith said
...general medicine Asit Parikh said many patients suffering from ulcerative colitis and Crohn's disease are eagerly awaiting new treatment options. "We are striving to accelerate the development of this drug to deliver this effective and highly anticipated treatment option for patients in Japan as soon as possible" Parikh said...

More Content

All (28) | News (13) | Reports (0) | Blogs (14) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Opportunity for emerging agents in Crohn’s dise... [Published Pharma Letter - Sep 18 2014]
Consumer Reports shares best buy for treating C... [Published EMax Health - Sep 03 2014]
Sofosbuvir and vedolizumab knocked back [Published Gastroenterology Update - Sep 02 2014]
Takeda launches first gut-selective treatment f... [Published Pharma Letter - Aug 28 2014]
Drug hope for Crohn's patients: New treatment i... [Published NewsRT.co.uk - Aug 28 2014]
Drug hope for Crohn's patients: New treatment i... [Published Mail Online UK - Aug 28 2014]
Three UC drugs approved by FDA [Published Orthopedics Today - Aug 25 2014]
Top medicine articles for July 2014 [Published Clinical Cases and Images: CasesBlog - Jul 23 2014]
ENTYVIO™ (vedolizumab) Now Available in the Uni... [Published PR Newswire: General Business - Jun 16 2014]
May's top stories: Bayer's $14.2bn Merck deal, ... [Published Pharmaceutical Technology - Jun 06 2014]
Takeda Receives European Commission Marketing A... [Published PRESSEMITTEILUNGEN - May 27 2014]
Takeda Receives European Commission Marketing A... [Published Nycomed News RSS feed - May 26 2014]
ENTYVIO (Vedolizumab) Injection, Powder, Lyophi... [Published DailyMed Drug Label Updates for the last seven ... - May 23 2014]
Takeda's Entyvio gets FDA approval to treat ulc... [Published PBR - News - May 21 2014]
Entyvio Approved for Ulcerative Colitis and Cro... [Published Yahoo! Health News - May 21 2014]
FDA Approves Takeda's Entyvio™ (vedolizumab) fo... [Published PR Newswire: Policy & Public Interest - May 20 2014]
FDA Approves Takeda's Entyvio™ (vedolizumab) fo... [Published Nycomed News RSS feed - May 20 2014]
Takeda's Entyvio Wins FDA OK for Severe Colitis [Published MedPageToday.com - medical news plus CME for ph ... - May 20 2014]
For Treatment of Ulcerative Colitis (UC), Great... [Published PR Newswire: General Business - Apr 21 2014]
EMA committee issues positive opinion for Taked... [Published Pharmaceutical Business Review - Mar 24 2014]
Takeda Receives Positive CHMP Opinion for Entyv... [Published Nycomed News RSS feed - Mar 23 2014]
Vedolizumab and IBD - IBD in the News [Published Mayo Clinic - YouTube - Feb 11 2014]
Research and Markets: Gastroenterology Thought ... [Published Business Wire Health News - Feb 11 2014]
Crohn's Disease Market to Show Modest Growth to... [Published Pharmaceutical Executive - Feb 04 2014]
Takeda starts two Phase III trials of vedolizum... [Published Pharmaceutical Business Review - Jan 09 2014]
FDA extends PDUFA action date for Takeda’s vedo... [Published Pharmaceutical Business Review - Dec 27 2013]
Takeda inks license & option pact with Natrogen... [Published PharmaBiz - Dec 24 2013]
US FDA committee recommends approval of Takedaâ... [Published PharmaBiz - Dec 11 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Top medicine articles for July 2014 [Published Clinical Cases and Images: CasesBlog - Jul 23 2014]
A collection of some interesting medical articles published recently: Migraines Linked to Increased Risk of 'Silent Strokes' http://buff.ly/1hTE5Ru Doctor’s Salaries Are Not the Big Cost - NYTimes http://buff.ly/QWe2lx  -- "There is a startling ...
ENTYVIO™ (vedolizumab) Now Available in the Uni... [Published PR Newswire: General Business - Jun 16 2014]
DEERFIELD, Ill., and OSAKA, Japan, June 16, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced the United States (U.S.) commercial availability of ...
Takeda Receives European Commission Marketing A... [Published PRESSEMITTEILUNGEN - May 27 2014]
Zurich And Osaka, Japan (ots/PRNewswire) – Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission (EC) has granted Marketing Authorisation for Entyvio(R) ...
Takeda Receives European Commission Marketing A... [Published Nycomed News RSS feed - May 26 2014]
Zurich, Switzerland, May 27th, 2014 and Osaka, Japan, May 28th, 2014 – Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission (EC) has granted Marketing ...
ENTYVIO (Vedolizumab) Injection, Powder, Lyophi... [Published DailyMed Drug Label Updates for the last seven ... - May 23 2014]
Updated Date: May 23, 2014 EST ...
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.